Inhalation Drugs

GSK Seeks to Expand its Respiratory Biologics Portfolio with Aiolos Acquisition

February 21, 2024

GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.

Breathing Easier

November 02, 2023

A novel approach for safety assessments in inhalation drugs may avoid animal testing for drug products.

Discussing Soft Mist Inhaler Technology with Marcel Baumann (World Vaccine Conference 2023)

April 04, 2023

Marcel Baumann, business development director at Recipharm, discusses soft mist inhaler technology from the show floor at the World Vaccine Conference.

Next Step in Clinical Development of Respiratory Drug Candidate SPX-001 Confirmed

November 28, 2022

SPX-001, a respiratory drug candidate, will be submitted through a combined Clinical Trial and Ethics Committee application for further advancement in the clinical stages.

Lonza Joins IPAC-RS, an International Consortium Advancing the Regulatory Science of Inhalation Products

April 05, 2022

Lonza has joined IPAC-RS, providing benefits to Lonza’s inhalation- related businesses due to IPAC-RS’ global voice of the orally inhaled and nasal drug products industry.

AstraZeneca Progresses Ambition Zero Carbon Program with Honeywell Partnership to Develop Next-Generation Respiratory Inhalers

February 24, 2022

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers as part of AstraZeneca’s Ambition Zero Carbon program.